CORDIS
Forschungsergebnisse der EU

CORDIS

Deutsch DE
European Consortium for Anticancer Antibody Development

European Consortium for Anticancer Antibody Development

Ziel

Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. Rapid and efficient translation of basic scientific advances into reagents, and targeted molecular leads for preclinical and clinical research and development based on scientific rationales and state-of-the-art technologies, optimally requires an interdisciplinary, collaborative, team-oriented approach. EUCAAD represents a virtual research institute in Europe and consists of 9 research participants including 4 SMEs devoted to the discovery and evaluation of new antibodies for therapy of human cancers. The consortium consists of researchers from SMEs and scientific and clinical centres that have gained international acclaim in this area of research, many of who have worked together in previous EU funded applications e.g. ANGIOSTOP, EUCAPS, ESTDAB and ENACT. Within the consortium there is unique expertise regarding target discovery, target validation, antibody production and initiation of clinical trials. As part of its efforts to translate laboratory research into viable cancer therapies the individual partners has accumulated an extensive portfolio of intellectual property providing a competitive edge to this application. The focus of the grant is the development and evaluation of antibodies against new target structures on tumour cells and blood vessels supplying tumours which are responsible for tumour angiogenesis, progression and metastasis. Collectively, the activities of this consortium can improve the cancer treatment standards in Europe and provide economic benefit to European biotechnology and pharmaceutical research by providing novel immunopharmaceuticals.

Koordinator

KAROLINSKA INSTITUTET

Adresse

Nobels Vag 5
17177 Stockholm

Schweden

Aktivitätstyp

Higher or Secondary Education Establishments

EU-Beitrag

€ 2 286 109,90

Kontakt Verwaltung

Maria Von Witting (Ms.)

Beteiligte (8)

Alphabetisch sortieren

Nach EU-Beitrag sortieren

Alles aufklappen

BIOINVENT INTERNATIONAL AB

Schweden

EU-Beitrag

€ 1 068 920

UNIVERSITE D'AIX MARSEILLE

Frankreich

EU-Beitrag

€ 532 098

THROMBOGENICS NV

Belgien

MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG

Deutschland

EU-Beitrag

€ 425 361

UNIVERSITA DEGLI STUDI DI TORINO

Italien

EU-Beitrag

€ 637 504

PHILOCHEM AG

Schweiz

EU-Beitrag

€ 309 206,80

PROTAGEN AG

Deutschland

EU-Beitrag

€ 456 640,70

UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA

Italien

EU-Beitrag

€ 274 021,60

Projektinformationen

ID Finanzhilfevereinbarung: 200755

Status

Abgeschlossenes Projekt

  • Startdatum

    1 Mai 2008

  • Enddatum

    30 April 2012

Finanziert unter:

FP7-HEALTH

  • Gesamtbudget:

    € 7 862 359,53

  • EU-Beitrag

    € 5 989 862

Koordiniert durch:

KAROLINSKA INSTITUTET

Schweden